Abstract:Aneurysmal subarachnoid hemorrhage (SAH) causes high rates of mortality and morbidity. A covered stent is an effective endovascular treatment for complicated aneurysms intractable to endovascular coiling and surgical clipping. However, in-stent restenosis and delayed endothelialization are the main challenges contributing to its safety. In this study, we designed a biofunctional stent covered with dual drug-loaded electrospun fibers to achieve programmed vascular endothelial growth factor (VEGF) and paclitaxel (PTX) release for the early promotion of stent endothelialization and long-term inhibition of stenosis caused by smooth muscle hyperplasia. By encapsulating PTX-loaded mesoporous silica nanoparticles (MSNs) within electrospun polylactic acid (PLA) fibers, the release period of PTX was effectively extended. Furthermore, VEGF was conjugated onto the surface of the membrane by reacting with polydopamine (PDA) for quick release. The in vitro drug release profile revealed the sustained release of PTX, which persisted for 63 days without early burst release, while up to 87.05% of VEGF was rapidly released within 3 days. After 6 days of incubation, cell experiments demonstrated that the dual drug-loaded scaffold effectively prompted endothelial cell proliferation (488% vs. 386% in the control group, P = 0.001) and inhibited the proliferation of smooth muscle cells (SMCs) using the 21-day extracts (155% vs. 303% in the control group, P = 0.039). Animal studies showed that compared to bare stents, the drug-loaded covered stents improved the immediate- and mid-term complete aneurysm occlusion rates (P < 0.05). The drug-loaded covered stents also showed earlier endothelialization promotion and better lumen restenosis than normal covered stents (0% vs. 25%, P = 0.29) for 12 weeks. Overall, a programmed dual drug-loaded scaffold that effectively occluded the aneurysm sac was developed in this study, and the discrete release of VEGF and PTX promoted endothelialization and prevented in-stent stenosis. This study provided a new method to improve the biosafety of implanted covered stents for the treatment of intracranial aneurysms. STATEMENT OF SIGNIFICANCE: Aneurysmal subarachnoid hemorrhage (SAH) is one of the most common hemorrhage stroke resulted in a nearly 40% mortality and 33% morbidity due to sudden rupture of an intracranial aneurysm. Endovascular coil embolism is a popular treatment for aneurysm but this technique run high risk of bleeding, mass effect, low complete occlusion rate and higher recanalization rate due to its operation conducted within aneurysm sac. A bio-functional membrane knitted by dual-drug loaded electrospun fibers covered on a stent was designed to realize programed vascular endothelial growth factor and paclitaxel release for the early promotion of vascular endothelium and long-term inhibition of stenosis caused by smooth muscle hyperplasia. This study provides new method to improve the biosafety of covered stent insertion for the treatment of intracranial aneurysms.

Controlled Delivery of Rosuvastatin or Rapamycin through Electrospun Bismuth Nanoparticle-Infused Perivascular Wraps Promotes Arteriovenous Fistula Maturation

Bismuth-infused perivascular wrap facilitates delivery of mesenchymal stem cells and attenuation of neointimal hyperplasia in rat arteriovenous fistulas

A TEMPOL and rapamycin loaded nanofiber-covered stent favors endothelialization and mitigates neointimal hyperplasia and local inflammation

Liposomal surface coatings of metal stents for efficient non-viral gene delivery to the injured vasculature

Electrospun Chitosan-Based Nanofibrous Coating for the Local and Sustained Release of Vancomycin

Rosuvastatin- and Heparin-Loaded Poly(l-lactide- Co-Caprolactone) Nanofiber Aneurysm Stent Promotes Endothelialization Via Vascular Endothelial Growth Factor Type A Modulation.

An Atorvastatin Calcium and Poly(l-Lactide-co-caprolactone) Core-Shell Nanofiber-Covered Stent to Treat Aneurysms and Promote Reendothelialization

Heparin and Vascular Endothelial Growth Factor Loaded Poly(L-lactide-co-caprolactone) Nanofiber Covered Stent-Graft for Aneurysm Treatment

Improving arteriovenous fistula patency: Transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation

REDV/Rapamycin-loaded Polymer Combinations As a Coordinated Strategy to Enhance Endothelial Cells Selectivity for a Stent System.

In Vitro and in Vivo Evaluation of Rapamycin-eluting Nanofibers Coated on Cardia Stents

Heparin- and Rosuvastatin- loaded Poly(L-lactide-co-caprolactone) Nanofiber Aneurysm Covered Stent Inhibits Inflammatory Smooth Muscle Cell in Reducing in-stent Stenosis and Thrombosis

An Electrospun Fiber-Covered Stent with Programmable Dual Drug Release for Endothelialization Acceleration and Lumen Stenosis Prevention.

PC220. Rapamycin Alters Venous Remodeling to Improve Arteriovenous Fistula Patency

Controlled release of vancomycin from PEGylated fibrinogen polyethylene glycol diacrylate hydrogel

Targeted Rapamycin Delivery via Magnetic Nanoparticles to Address Stenosis in a 3D Bioprinted in Vitro Model of Pulmonary Veins

Bioinspired Vascular Stents with Microfluidic Electrospun Multilayer Coatings for Preventing in‐stent Restenosis

Poly(Lactic-Co-Glycolic Acid) Microparticles for the Delivery of Model Drug Compounds for Applications in Vascular Tissue Engineering

Tuning Recombinant Perlecan Domain V to Regulate Angiogenic Growth Factors and Enhance Endothelialisation of Electrospun Silk Vascular Grafts

A pDNA/rapamycin nanocomposite coating on interventional balloons for inhibiting neointimal hyperplasia

Enabling Topical and Long-Term Anti-Radical Properties for Percutaneous Coronary Intervention-Related Complications by Incorporating TEMPOL into Electrospun Nanofibers